{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:54:35Z","timestamp":1773215675841,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"3-4","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1053\/j.seminoncol.2024.02.002","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T13:10:57Z","timestamp":1709557857000},"page":"77-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["RENO Study: Clinical characteristics, treatment patterns and survival results in patients with metastatic renal cell carcinoma in Northern Spain"],"prefix":"10.1053","volume":"51","author":[{"given":"Laura Basterretxea","family":"Badiola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria Lainez","family":"Milagro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego Cacho","family":"Lav\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra L\u00f3pez","family":"Peraita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikel Arruti","family":"Ibarbia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireia Mart\u00ednez","family":"Kareaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa de Portugal","family":"Fern\u00e1ndez del Rivero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego Soto de Prado","family":"Otero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valent\u00edn Alija","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos \u00c1lvarez","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra Lacalle","family":"Emborujo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene Gil","family":"Arnaiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo Fern\u00e1ndez","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Verd\u00fan-Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naiara","family":"Sagastibeltza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Duran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.seminoncol.2024.02.002_bib0001","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","article-title":"The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma","volume":"23","author":"Ricketts","year":"2018","journal-title":"Cell Rep"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0002","unstructured":"World Health Organization, Cancer Today; https:\/\/gco.iarc.fr\/today\/factsheets-cancers). https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/29-Kidney-fact-sheet.pdf."},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0003","unstructured":"Kidney Cancer Statistics. https:\/\/www.cancer.net\/cancer-types\/kidney-cancer\/statistics."},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0004","unstructured":"Cancer Stat Facts: Kidney and Renal Pelvis Cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html."},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0005","unstructured":"Cancer Incidence in Five Continents. Arci. WHO. https:\/\/ci5.iarc.fr."},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0006","unstructured":"Cancer de ri\u00f1on. https:\/\/mdanderson.es\/elcancer\/elcancerdelaaalaz\/cancer-de-rinon."},{"issue":"Suppl 1","key":"10.1053\/j.seminoncol.2024.02.002_bib0007","first-page":"S55","article-title":"Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma","volume":"6","author":"Fisher","year":"2000","journal-title":"Cancer J Sci Am"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0008","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2005.03.206","article-title":"Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma","volume":"23","author":"McDermott","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0009","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1200\/JCO.2000.18.16.2972","article-title":"Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma","volume":"18","author":"Motzer","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0010","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199804303381805","article-title":"Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma","volume":"338","author":"Negrier","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0011","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2003.02.122","article-title":"Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer","volume":"21","author":"Yang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0012","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0013","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0014","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0015","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0016","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0017","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0018","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0019","unstructured":"National Comprehensive Cancer Network. Kidney cancer version 4.2023."},{"issue":"12","key":"10.1053\/j.seminoncol.2024.02.002_bib0020","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1093\/annonc\/mdt397","article-title":"Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials","volume":"24","author":"Templeton","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2023.102409","article-title":"Biological sex disparity in survival outcomes following treatment for renal cell carcinoma: a systematic review and meta-analysis","volume":"86","author":"Nkemjika","year":"2023","journal-title":"Cancer Epidemiol"},{"issue":"9","key":"10.1053\/j.seminoncol.2024.02.002_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162864","article-title":"In-hospital economic burden of metastatic renal cell carcinoma in France in the era of targeted therapies: analysis of the French National Hospital database from 2008 to 2013","volume":"11","author":"Maroun","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1053\/j.seminoncol.2024.02.002_bib0023","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12885-018-4117-z","article-title":"Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: retrospective analysis of cross-sectional data","volume":"18","author":"Maroun","year":"2018","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1053\/j.seminoncol.2024.02.002_bib0024","article-title":"Real-world survival outcomes associated with first-line immunotherapy, targeted therapy, and combination therapy for metastatic clear cell renal cell carcinoma","volume":"4","author":"Chakiryan NH Gore","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2021.04.004","article-title":"Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials","volume":"151","author":"Gan","year":"2021","journal-title":"Eur J Cancer"},{"issue":"28","key":"10.1053\/j.seminoncol.2024.02.002_bib0026","article-title":"Real-world outcomes in patients with metastatic renal cell carcinoma treated with first-line nivolumab plus ipilimumab","volume":"39","author":"Doshi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0027","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003281","article-title":"Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab","volume":"9","author":"Brown","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.803935","article-title":"Real-world metastatic renal cell carcinoma treatment patterns and clinical outcomes in the Netherlands","volume":"13","author":"Van Laar","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0029","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.euros.2022.12.015","article-title":"Real-world treatment patterns and clinical outcomes for metastatic renal cell carcinoma in the current treatment era","volume":"49","author":"Shah","year":"2023","journal-title":"Eur Urol Open Sci"},{"issue":"2","key":"10.1053\/j.seminoncol.2024.02.002_bib0030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol"},{"issue":"34","key":"10.1053\/j.seminoncol.2024.02.002_bib0031","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0032","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2014.04.006","article-title":"A systematic review of sequencing and combination of systemic therapy in metastatic renal cancer","volume":"67","author":"Albiges","year":"2015","journal-title":"Eur Urol"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0033","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/ajh.21942","article-title":"Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?","volume":"86","author":"Zackova","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0034","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3233\/CBM-2011-0176","article-title":"Renal cell carcinoma","volume":"9","author":"Cairns","year":"2010","journal-title":"Cancer Biomark"},{"issue":"5","key":"10.1053\/j.seminoncol.2024.02.002_bib0035","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.seminoncol.2024.02.002_bib0036","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0037","unstructured":"Acuerdos De La Reuni\u00f3n De La Comisi\u00f3n Interministerial De Precios De Los Medicamentos. https:\/\/www.sanidad.gob.es\/profesionales\/farmacia\/pdf\/20211025_ACUERDOS_CIPM_EXTRAORDINARIA_2162.pdf."},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0038","doi-asserted-by":"crossref","first-page":"299","DOI":"10.14694\/EdBook_AM.2012.32.25","article-title":"The evolving landscape of metastatic renal cell carcinoma","author":"Heng","year":"2012","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"18 Pt 2","key":"10.1053\/j.seminoncol.2024.02.002_bib0039","doi-asserted-by":"crossref","first-page":"6302S","DOI":"10.1158\/1078-0432.CCR-040031","article-title":"Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience","volume":"10","author":"Motzer","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1053\/j.seminoncol.2024.02.002_bib0040","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ejca.2013.11.020","article-title":"Small renal cell carcinomas\u2013how dangerous are they really? Results of a large multicenter study","volume":"50","author":"Steffens","year":"2014","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1053\/j.seminoncol.2024.02.002_bib0041","doi-asserted-by":"crossref","first-page":"610","DOI":"10.5489\/cuaj.978","article-title":"Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy","volume":"2","author":"Karakiewicz","year":"2008","journal-title":"Can Urol Assoc J"},{"issue":"5","key":"10.1053\/j.seminoncol.2024.02.002_bib0042","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/bjc.2013.832","article-title":"Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma","volume":"110","author":"Hutson","year":"2014","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1053\/j.seminoncol.2024.02.002_bib0043","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.eururo.2013.10.013","article-title":"The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium","volume":"65","author":"Schutz","year":"2014","journal-title":"Eur Urol"},{"issue":"4","key":"10.1053\/j.seminoncol.2024.02.002_bib0044","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.eururo.2014.05.034","article-title":"Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"66","author":"Heng","year":"2014","journal-title":"Eur Urol"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0045","doi-asserted-by":"crossref","DOI":"10.1007\/s00432-023-04645-x","article-title":"Sequential treatment of metastatic renal cell carcinoma patients after first-line vascular endothelial growth factor targeted therapy in a real-world setting: epidemiologic, noninterventional, retrospective-prospective cohort multicentre study","author":"Cesas","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminoncol.2024.02.002_bib0046","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdv601","article-title":"Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study","volume":"27","author":"P\u00e9rez-Valderrama","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2024.02.002_bib0047","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.2147\/OTT.S141260","article-title":"Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib","volume":"10","author":"Koutsoukos","year":"2017","journal-title":"Onco Targets Ther"},{"issue":"9","key":"10.1053\/j.seminoncol.2024.02.002_bib0048","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s12094-020-02288-9","article-title":"Eastern Spanish experience with nivolumab in metastatic renal cell carcinoma","volume":"22","author":"Jos\u00e9","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"7","key":"10.1053\/j.seminoncol.2024.02.002_bib0049","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.acuro.2019.03.005","article-title":"Safety of nivolumab in metastatic renal cell carcinoma patients: a real-life experience in a Spanish urology setting","volume":"43","author":"Amores Berm\u00fadez","year":"2019","journal-title":"Actas Urol Esp (Engl Ed)"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775424000058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775424000058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T09:06:59Z","timestamp":1722503219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775424000058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":49,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0093775424000058"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2024.02.002","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RENO Study: Clinical characteristics, treatment patterns and survival results in patients with metastatic renal cell carcinoma in Northern Spain","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2024.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}